



Liberty Health Sciences To Launch Zentient Labs CBD Portfolio Of Products

Liberty offers range of premium, natural hemp-based products of ultra-high-quality CBD, nutraceuticals and vitamins designed to enhance health and wellness

Toronto, ON – December 20, 2018 — Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high quality cannabis, today announced the launch of Zentient Labs, a line of premium hemp-based CBD products made from a proprietary formula of ultra-high quality CBD, nutraceuticals and vitamins that promote energy and focus for wellness seekers.



The CBD market is experiencing dramatic growth and is predicted to grow to \$2.1 billion in consumer sales by 2020, with \$450 million of those sales coming from hemp-based sources. Demand for CBD has also increased rapidly due in large part to the wide variety of ways it can be used in products, ranging from food and cosmetics to beverages and a myriad of health supplements.

“Liberty Health Sciences is quickly becoming a leading cultivator and distributor of premium cannabis products through low-cost production techniques and high-end dispensary design and intends to apply the same techniques to the cultivation and distribution of hemp-derived products,” said George Scorsis, CEO of Liberty Health Sciences. “We currently operate two facilities in Florida with a total cultivation capacity of over 41,000 square feet.

“The Company has increased its cultivation capacity to more than 120,000 square feet and will grow to approximately 225,000 square feet by early 2019. Our processing facility utilizes state-of-the-art equipment and techniques for extraction and purification and our experience with medical marijuana is directly applicable to industrial hemp,” said Scorsis.

Zentient Labs will include a line of products across numerous categories including propriety brands and partner brands. These categories will include an athletic line, a wellness line, beauty and premium pet products.

Liberty carefully selected the brand name Zentient Labs to deliver on a promise to provide high-quality CBD products to customers who seek out creative pursuits, the deepest of relaxation and the most aggressive sports activities. The Company did extensive consumer research to define what this brand will represent.

“Zentient Labs’ line of wellness products was designed to support your desired activity, so you can be in the ‘Zentient Zen state’, as we call it,” said Stephanie Kubacki, Vice President of Marketing, Liberty Health Sciences. “When ‘in the zone’, you become one with the activity, lost in the rhythm of the tasks at hand. It’s characterized by complete connectedness and presence, being solely focused on that exact moment in time. This is what our exciting line of products looks to support. Let’s face it, with the pace of life these days, many of us strive to be more conscious and in the now.”

Liberty used the services of Theory SF www.theorysf.com, a multi-disciplinary marketing agency located in the heart of San Francisco to create the Zentient Labs brand image.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries, and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Media Contacts:

Dwain Schenck
203-223-5230
dwain@schenckstrategies.com

Stephanie Kubacki
Vice-President, Marketing
415-830-7337
skubacki@libertyhealthsciences.com